Antibiotic resistance: causes, consequences and public-health responses

How resistance develops and spreads

Resistance can arise in individual bacteria by random genetic changes and then spread within and between species. Two broad mechanisms are common:

• Genetic mutation: spontaneous changes in a bacterium's DNA can alter the drug target or reduce uptake, making the cell less susceptible.
• Horizontal gene transfer: resistance genes carried on plasmids, transposons or bacteriophages move between bacteria, sometimes across species boundaries, allowing rapid dissemination.

These processes are driven by selective pressure when antibiotics are present: susceptible cells die or stop growing, while resistant ones proliferate. Once established, resistance traits can be maintained even without continued drug exposure.

Major drivers and settings

Several human activities accelerate the emergence and spread of resistance. Overuse and inappropriate prescribing of antibiotics in primary care, widespread use in livestock and aquaculture for growth promotion or disease prevention, poor infection prevention and control in healthcare facilities, and environmental contamination are all factors. Global travel and trade also spread resistant strains rapidly across regions. These issues have surprised many researchers, including microbiologists, because resistance can move faster than expected.

Consequences for health and medicine

Antibiotic resistance increases the risk that common infections will become harder or impossible to treat, raising illness severity, duration, and mortality. It undermines routine medical procedures that rely on effective prophylaxis and treatment of infections, from elective surgery to treatments in medicine such as chemotherapy and organ transplantation. Resistance also raises healthcare costs through longer hospital stays, additional tests, and more expensive or toxic drug regimens.

History, innovation and the drug pipeline

Since the mid-20th century many antibiotics were discovered and developed, but the pace of discovery slowed: relatively few new classes of antibiotics have entered clinical use since the late twentieth century. Research continues, and there have been recent approvals and experimental agents, yet developing new antibiotics remains scientifically challenging, slow and expensive. The interval from discovery to widely available therapy can span many years, and market incentives for pharmaceutical companies are limited because new antibiotics are often held in reserve to limit resistance.

Responses: prevention, stewardship and research

Addressing antibiotic resistance requires coordinated actions across sectors. Key approaches include:

• Antibiotic stewardship: rational prescribing, shorter courses when appropriate, and avoiding unnecessary use in humans and animals.
• Infection prevention: hygiene, vaccination, safe food-handling, and hospital infection control to limit spread.
• Surveillance and diagnostics: rapid tests to guide therapy and monitoring of resistance trends.
• Research and incentives: new drugs, alternative therapies (for example phage therapy or vaccines), and financial models to encourage development.

Combating resistance is a long-term global challenge that combines public-health policy, clinical practice, agricultural change and scientific innovation. For further reading and policy resources see antibiotics overview, technical literature and international guidance at evolutionary and microbiology portals.

Surgery | Medicine | Microbiologists' perspectives